Equities analysts expect Genprex Inc (NASDAQ:GNPX) to report ($0.21) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Genprex’s earnings. Genprex posted earnings per share of ($0.45) during the same quarter last year, which would indicate a positive year-over-year growth rate of 53.3%. The business is expected to announce its next earnings results on Tuesday, August 13th.
According to Zacks, analysts expect that Genprex will report full year earnings of ($0.87) per share for the current fiscal year. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that cover Genprex.
Genprex (NASDAQ:GNPX) last released its earnings results on Wednesday, May 15th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.09.
A number of research analysts recently weighed in on the stock. Noble Financial assumed coverage on shares of Genprex in a research report on Monday, April 29th. They issued an “outperform” rating and a $5.00 target price for the company. Zacks Investment Research raised shares of HAYS PLC/ADR from a “sell” rating to a “hold” rating in a research report on Tuesday, June 18th. Finally, Maxim Group reissued a “hold” rating on shares of Cytori Therapeutics in a research report on Monday, April 1st.
Genprex stock traded up $0.01 during mid-day trading on Friday, reaching $1.07. The company’s stock had a trading volume of 100 shares, compared to its average volume of 32,331. The stock has a market cap of $17.32 million, a P/E ratio of -1.18 and a beta of 1.49. Genprex has a 12 month low of $0.95 and a 12 month high of $7.95. The firm’s 50 day simple moving average is $1.38.
Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.
Featured Article: SEC Filing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.